当前位置:首页 - 行情中心 - 南华生物(000504) - 财务分析 - 利润表

南华生物

(000504)

  

流通市值:26.87亿  总市值:28.55亿
流通股本:3.11亿   总股本:3.30亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入104,759,853.1470,433,702.634,739,572.68200,345,457.02
营业收入104,759,853.1470,433,702.634,739,572.68200,345,457.02
二、营业总成本113,192,341.1275,767,566.5535,814,358.27207,266,211.43
营业成本34,369,291.0923,714,714.3610,871,092.3670,538,085.33
税金及附加780,810.1495,481.39213,636.091,122,264.45
销售费用27,696,562.518,423,602.238,743,639.4860,431,047.09
管理费用36,577,431.724,312,254.7611,823,853.1653,603,083.01
研发费用6,938,971.614,360,387.522,197,527.499,985,226.68
财务费用6,829,274.124,461,126.291,964,609.6911,586,504.87
其中:利息费用7,651,305.595,205,561.232,740,409.0211,867,812.11
其中:利息收入1,699,336.641,391,888.45874,563.761,776,973.77
加:公允价值变动收益-213,829.32-82,297.17-15,609.37-58,884.47
加:投资收益787,244.74576,554.57214,734.953,855.43
资产处置收益13,766,369.69-54,247.78-84,586.28
资产减值损失(新)-2,359.18-2,359.18--2,119,074.96
信用减值损失(新)-2,435,816.22-2,435,816.22--24,671,556.24
其他收益1,396,589.58926,826.4709,419.537,532,484.32
营业利润平衡项目0000
四、营业利润4,865,711.31-6,405,203.33-166,240.48-26,149,344.05
加:营业外收入1,006,310.41,000,912.171,000,0004,632,297.63
减:营业外支出1,888.531,1991,19942,370.01
利润总额平衡项目0000
五、利润总额5,870,133.18-5,405,490.16832,560.52-21,559,416.43
减:所得税费用1,160,896.78415,923.53394,692.418,202,003.82
六、净利润4,709,236.4-5,821,413.69437,868.11-29,761,420.25
持续经营净利润4,709,236.4-5,821,413.69437,868.11-29,761,420.25
归属于母公司股东的净利润486,718.3-8,973,155-1,976,045.11-12,694,776.12
少数股东损益4,222,518.13,151,741.312,413,913.22-17,066,644.13
(一)基本每股收益0-0.03-0.01-0.04
(二)稀释每股收益0-0.03-0.01-0.04
九、综合收益总额4,709,236.4-5,821,413.69437,868.11-29,761,420.25
归属于母公司股东的综合收益总额486,718.3-8,973,155-1,976,045.11-12,694,776.12
归属于少数股东的综合收益总额4,222,518.13,151,741.312,413,913.22-17,066,644.13
公告日期2023-10-312023-08-302023-04-292023-04-21
审计意见(境内)标准无保留意见
TOP↑